If you search "GHK-Cu hair growth" today, you will find the same photo set and the same number quoted everywhere: a median 26.5% regrowth over the top of the scalp. It is a real, peer-reviewed figure from a 2025 dermatology paper. It is also one of the clearest examples in the peptide space of a result being attributed to the wrong ingredient. In that study, the copper peptide was tattooed into the scalp alongside minoxidil and dutasteride — two of the best-evidenced hair drugs in existence — in seven men, with no arm that left the copper out. This post is a look at what GHK-Cu research can and cannot tell us about hair, and where Australian rules sit on topical versus injectable use.

For background on the molecule itself, see our GHK-Cu profile.

What is GHK-Cu, and why did anyone try it on scalps?

GHK-Cu is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) bound to a copper(II) ion. It is found in human plasma and appears at wound sites, where it behaves less like a single-target drug and more like a local coordinator of repair: attracting immune cells, stimulating fibroblasts, driving collagen and glycosaminoglycan synthesis, and promoting new blood vessel formation via VEGF signalling. Gene-expression work summarised by Pickart and Margolina reported that GHK influences a very large number of human genes in cultured cells — a finding that is mechanistically interesting and also the source of most of the internet's overreach.

The hair rationale follows from the vasculature and the dermal papilla: if a peptide enlarges follicles and improves perifollicular blood supply in animal and cell models, it is not unreasonable to test it on androgenetic alopecia. Reasonable hypothesis, thin human evidence.

The 26.5% number, and what it actually measured

The study behind the viral figure is Kuceki and colleagues in JAAD International (published online February 2025). Researchers used a rotary tattoo machine to deposit a solution of 0.5% minoxidil sulfate, 0.1% dutasteride and 1.2% copper peptides into the scalps of men with Norwood-Hamilton III–IV pattern loss, across five monthly sessions.

Reported outcomes: median top-scalp area regrowth of 26.5% (IQR 15.3–32.8%), and median blinded Severity of Alopecia Tool scores falling from 40.0% at baseline to 7.5%.

Now the caveats, which matter more than the headline:

  • Seven patients. This was a retrospective analysis of seven men treated in 2018–2019 after inadequate response to at least a year of standard therapy.
  • No control arm, and no copper-free comparator. The 26.5% was contrasted against a previously published cohort that received three sessions of minoxidil-dutasteride tattooing (median 10%). That comparison changes two variables at once — it adds copper peptides and two extra treatment sessions. You cannot separate them.
  • Two potent co-administered drugs. Minoxidil and dutasteride have large, replicated efficacy datasets in androgenetic alopecia. Attributing a combination result to the least-evidenced ingredient is not how attribution works.
  • Assessment methods were unusual. Blinded dermatologist scoring was supplemented by a large language model's visual estimation of scalp visibility, used because trichoscopy images were unavailable.

None of that makes the study worthless — it is a legitimate proof-of-concept for intradermal drug delivery. It simply is not evidence that GHK-Cu grows hair.

The older copper-peptide hair data

Enthusiasts usually point further back, to late-1990s work on a roughly 0.1% copper-peptide scalp formulation developed by ProCyte (marketed as Tricomin), which was reported at the time to increase hair density and reduce shedding. Trade coverage from that era confirms trials were run, but much of the detail circulated as company announcements and conference material rather than fully reported randomised trials, and we could not locate a modern replication. Treat it as historical signal, not settled evidence.

Where GHK-Cu evidence is genuinely stronger: skin and wounds

The contrast is instructive. In skin, GHK-Cu has controlled cosmetic studies and a large preclinical wound-healing literature — accelerated wound closure, better graft integration and increased angiogenesis across multiple animal models, plus formulation work suggesting liposomal delivery outperforms free peptide in scald models. A 2025 review of tripeptides in wound repair makes the key limitation explicit: measuring how much peptide actually reaches the target tissue remains a methodological problem that holds back clinical translation. That is the honest state of play — plausible mechanism, decent cosmetic-endpoint data, animal-heavy healing data, and no large human outcome trials.

Anyone browsing clinical trial registries for GHK-Cu should also check the sponsor name against a real-world organisation before quoting a listing. Registry entries are self-submitted, and a listing alone is not evidence of a funded, running program. More context on how we weigh this sort of evidence sits in our peptides section.

Is GHK-Cu legal in Australia?

This is the question that drives most of the local search traffic, and the answer depends entirely on the route.

Topical, cosmetic use is legal. Copper peptide serums and creams are sold in Australia as cosmetics, and this is the form with actual controlled human cosmetic data behind it.

Injectable GHK-Cu is unapproved. The TGA's April 2026 safety alert on unregulated peptides explicitly named GHK-Cu alongside BPC-157, TB-500, CJC-1295 and retatrutide as compounds circulating in unapproved injectable form, citing reports including severe allergic reactions. It remains illegal to import, manufacture or supply unapproved therapeutic goods in Australia. There is no TGA-registered injectable GHK-Cu product, and no approved indication for hair loss by any route.

Worth adding: the tattooing protocol above is not an approved delivery method for any of its three ingredients in Australia, and dutasteride is not registered here for androgenetic alopecia. It is a clinic-level investigational technique, not a product you can lawfully assemble at home.

The practical read

If your interest is skin texture and cosmetic endpoints, topical GHK-Cu sits in a defensible evidence bracket for a cosmetic ingredient. If your interest is hair, the honest summary is that GHK-Cu has never been isolated in a controlled human trial for androgenetic alopecia — every prominent modern result comes bundled with drugs that already work. That is the gap to watch, and the single study design that would close it: copper peptide versus vehicle, same delivery, same sessions, no minoxidil in the mix.

Want the next GHK-Cu study assessed the same way, without the marketing gloss? Join the free updates list.

FAQ

Does GHK-Cu work for hair loss?

There is no controlled human trial testing GHK-Cu on its own for androgenetic alopecia. The most-cited 2025 result combined copper peptides with minoxidil and dutasteride in seven men, so the effect cannot be attributed to GHK-Cu.

Is GHK-Cu legal in Australia?

Topical cosmetic GHK-Cu products are legal to sell and use. Injectable GHK-Cu is unapproved — the TGA named it in an April 2026 alert on unregulated peptides, and supplying or importing unapproved therapeutic goods is illegal.

What is GHK-Cu and how is it meant to work?

GHK-Cu is a naturally occurring copper-binding tripeptide found in plasma and at wound sites. It stimulates collagen synthesis, fibroblast activity and angiogenesis in laboratory and animal models, which is the basis for its cosmetic and wound-repair use.

Is injectable GHK-Cu better than topical for hair?

No human trial has compared them for hair outcomes. Injectable GHK-Cu is unapproved in Australia and carries sterility, dosing and allergic-reaction risks the TGA has specifically flagged.

Sources

This article is general information, not medical advice. retatrutide.net.au is independent and does not sell peptides. Topical cosmetic GHK-Cu is legal in Australia; injectable GHK-Cu is not TGA-approved for any indication.